Phase I and Phase II clinical trials of a combination of AstraZeneca and Sputnik Light coronavirus vaccines started in Russia on Monday. This is evidenced by data from the state register of approvals for such trials.
The safety and immunogenicity trials of the drug combination, which is administered under a "heterologous prime-boost" regimen, will be conducted in 150 adults. The study will conclude on March 2 next year.
The combination drug will be studied in three St. Petersburg institutions. They are Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, Pavlov First St. Petersburg Medical University and the Curator. The study will also take place in Moscow clinics "Oris" and "Medsi".
According to the registry, IQVA RDS GmbH in Moscow has been engaged as the developer.
Made in Russia // Made in Russia
Author: Ksenia Gustova